Info
ActiTrexx develops ATreg, activated regulatory T cells (Tregs), which are stimulated using a proprietary process, to prevent rejection reactions in transplanted patients and excessive immune responses in autoimmune diseases.
Actitrexx, a spin-off from the University Mainz, develops ATreg, a cellular therapy with activated regulatory T cells produced within 24hrs by a proprietary automated process. ATreg suppresses undesired immune responses and inflammatory reactions and will be clinically tested to treat and prevent Graft-versus-Host Disease and other autoimmune disorders.
